Here's a statement of the obvious: The opinions expressed here are those of the participants, not those of the Mutual Fund Observer. We cannot vouch for the accuracy or appropriateness of any of it, though we do encourage civility and good humor.
At the very least, if you're going to speculate on an early stage bio, ideally it's one with multiple compounds in trials. At least you've got multiple shots on goal. VSAR had one...not sure how it had the valuation it did. These companies as a class are tempting though for a small portion of a portfolio for speculation.
Comments